Physician profile
Kyle Stephen Kimura
NPI 1013361005
$1,357.11
in general payments reported to CMS, 2019-2025
13 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $42.30 · 2023: $822 · 2024: $307 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Travel and Lodging: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.81 |
| Travel and Lodging | $430.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $430.00 | 2023 | |
| Musculoskeletal Transplant Foundation INC. | $216.74 | 2023-2024 | |
| Kerecis Limited | $145.46 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genzyme Corporation | $143.56 | 2024-2025 | |
| Stryker Corporation | $124.99 | 2023-2024 | Na, Smartlock, Scopis Ent |
| Optinose US, INC. | $71.52 | 2024 | |
| Kls-Martin L.P. | $42.30 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $41.94 | 2024-2025 | Libtayo |
| Innovation Technologies INC | $37.02 | 2023 | Irrisept |
| Hologic Sales and Service, LLC | $31.76 | 2024 | Coolseal Generator |
| Sun Pharmaceutical Industries INC. | $25.07 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $23.96 | 2025 | |
| Glaxosmithkline, LLC. | $22.79 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.